Ryan Cawood

Chief Scientific Officer • WuXi Advanced Therapies

Ryan founded Oxford Genetics (trading as OXGENE) in 2011, after earning a degree in genetics and a PhD in gene therapy from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™. Ryan used his background in virology to guide and grow the business through a series of strategic changes that deployed the SnapFast™ technology for cell and gene therapy discovery and manufacturing applications. He has over 20 peer reviewed papers and is the inventor on more than 100 international patent applications. In 2021, Ryan led the sale of the OXGENE to WuXi Advanced Therapies. He is currently the Chief Scientific Officer for WuXi Advanced Therapies and OXGENE.

Also Speaking

Patrick Westmoreland

Principal Scientist, Viral Vector and Gene Editing Process Development  • Bristol Myer Squibb

Angela Justice

Chief People Officer • TCR2 Therapeutics

Dan Strange

Head of Cell Therapy Technology • TTP

Event Info


Fun Run